Acute myeloid leukemia and NK cells: two warriors confront each other
Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. Thes...
Gespeichert in:
| Veröffentlicht in: | Oncoimmunology 2019-02, Vol.8 (2), p.e1539617-e1539617 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1539617 |
|---|---|
| container_issue | 2 |
| container_start_page | e1539617 |
| container_title | Oncoimmunology |
| container_volume | 8 |
| creator | Baragaño Raneros, Aroa López-Larrea, Carlos Suárez-Álvarez, Beatriz |
| description | Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerful warriors that can bring about the lysis of tumor cells through their cytotoxic ability. However, tumor cells have developed strategies to evade recognition mediated by NKs. Here, we review the mechanisms triggered by AML cells and discuss the emerging immunotherapeutic strategies that potentiate the anti-tumor functions of NKs. |
| doi_str_mv | 10.1080/2162402X.2018.1539617 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_30713800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ef89548a3bb047768200302b1b59fa08</doaj_id><sourcerecordid>2179515324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-81e6ad7d4c2e75bd2c477a06fc5cf396f8635fb21085ee77ddc1fb5ffbf9e8e33</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EolXpTwD5yGUXf8SJwwFRVQUqKriAxM3yx7jr4sTFTljtv8dhtyt6wRdbM-8845kXoZeUrCmR5A2jLWsI-7FmhMo1FbxvafcEnS7x1ZJ4enxTeoLOS7kj9bREtLx_jk446SiXhJyiqws7T4CHHcQUHI4w_4QhaKxHh798xhZiLG_xtE14q3MOKRds0-hzGicM2m5wmjaQX6BnXscC54f7DH3_cPXt8tPq5uvH68uLm5UVvJlWkkKrXecay6ATxjHbdJ0mrbfC-jqDly0X3rA6owDoOucs9UZ4b3wPEjg_Q9d7rkv6Tt3nMOi8U0kH9TeQ8q3SeQo2ggIve9FIzY0htUsrGSGcMEON6L0msrLe7Vn3sxnAWRinrOMj6OPMGDbqNv1WLW_q7mgFvD4Acvo1Q5nUEMqyMD1CmotitOtF9YY1VSr2UptTKRn8sQ0lanFUPTiqFkfVwdFa9-rfPx6rHvyrgvd7QRh9yoPephydmvQupuyzHm0oiv-_xx8A2LBl</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179515324</pqid></control><display><type>article</type><title>Acute myeloid leukemia and NK cells: two warriors confront each other</title><source>PubMed Central</source><creator>Baragaño Raneros, Aroa ; López-Larrea, Carlos ; Suárez-Álvarez, Beatriz</creator><creatorcontrib>Baragaño Raneros, Aroa ; López-Larrea, Carlos ; Suárez-Álvarez, Beatriz</creatorcontrib><description>Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerful warriors that can bring about the lysis of tumor cells through their cytotoxic ability. However, tumor cells have developed strategies to evade recognition mediated by NKs. Here, we review the mechanisms triggered by AML cells and discuss the emerging immunotherapeutic strategies that potentiate the anti-tumor functions of NKs.</description><identifier>ISSN: 2162-4011</identifier><identifier>ISSN: 2162-402X</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.1080/2162402X.2018.1539617</identifier><identifier>PMID: 30713800</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Acute myeloid leukemia ; CAR-T ; immune checkpoints ; immunotherapy ; natural killer cells ; NKG2D ; Review</subject><ispartof>Oncoimmunology, 2019-02, Vol.8 (2), p.e1539617-e1539617</ispartof><rights>2018 Taylor & Francis Group, LLC 2018</rights><rights>2018 Taylor & Francis Group, LLC 2018 Taylor & Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-81e6ad7d4c2e75bd2c477a06fc5cf396f8635fb21085ee77ddc1fb5ffbf9e8e33</citedby><cites>FETCH-LOGICAL-c534t-81e6ad7d4c2e75bd2c477a06fc5cf396f8635fb21085ee77ddc1fb5ffbf9e8e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343801/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343801/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30713800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baragaño Raneros, Aroa</creatorcontrib><creatorcontrib>López-Larrea, Carlos</creatorcontrib><creatorcontrib>Suárez-Álvarez, Beatriz</creatorcontrib><title>Acute myeloid leukemia and NK cells: two warriors confront each other</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerful warriors that can bring about the lysis of tumor cells through their cytotoxic ability. However, tumor cells have developed strategies to evade recognition mediated by NKs. Here, we review the mechanisms triggered by AML cells and discuss the emerging immunotherapeutic strategies that potentiate the anti-tumor functions of NKs.</description><subject>Acute myeloid leukemia</subject><subject>CAR-T</subject><subject>immune checkpoints</subject><subject>immunotherapy</subject><subject>natural killer cells</subject><subject>NKG2D</subject><subject>Review</subject><issn>2162-4011</issn><issn>2162-402X</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kU1v1DAQhi0EolXpTwD5yGUXf8SJwwFRVQUqKriAxM3yx7jr4sTFTljtv8dhtyt6wRdbM-8845kXoZeUrCmR5A2jLWsI-7FmhMo1FbxvafcEnS7x1ZJ4enxTeoLOS7kj9bREtLx_jk446SiXhJyiqws7T4CHHcQUHI4w_4QhaKxHh798xhZiLG_xtE14q3MOKRds0-hzGicM2m5wmjaQX6BnXscC54f7DH3_cPXt8tPq5uvH68uLm5UVvJlWkkKrXecay6ATxjHbdJ0mrbfC-jqDly0X3rA6owDoOucs9UZ4b3wPEjg_Q9d7rkv6Tt3nMOi8U0kH9TeQ8q3SeQo2ggIve9FIzY0htUsrGSGcMEON6L0msrLe7Vn3sxnAWRinrOMj6OPMGDbqNv1WLW_q7mgFvD4Acvo1Q5nUEMqyMD1CmotitOtF9YY1VSr2UptTKRn8sQ0lanFUPTiqFkfVwdFa9-rfPx6rHvyrgvd7QRh9yoPephydmvQupuyzHm0oiv-_xx8A2LBl</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Baragaño Raneros, Aroa</creator><creator>López-Larrea, Carlos</creator><creator>Suárez-Álvarez, Beatriz</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190201</creationdate><title>Acute myeloid leukemia and NK cells: two warriors confront each other</title><author>Baragaño Raneros, Aroa ; López-Larrea, Carlos ; Suárez-Álvarez, Beatriz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-81e6ad7d4c2e75bd2c477a06fc5cf396f8635fb21085ee77ddc1fb5ffbf9e8e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute myeloid leukemia</topic><topic>CAR-T</topic><topic>immune checkpoints</topic><topic>immunotherapy</topic><topic>natural killer cells</topic><topic>NKG2D</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baragaño Raneros, Aroa</creatorcontrib><creatorcontrib>López-Larrea, Carlos</creatorcontrib><creatorcontrib>Suárez-Álvarez, Beatriz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baragaño Raneros, Aroa</au><au>López-Larrea, Carlos</au><au>Suárez-Álvarez, Beatriz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute myeloid leukemia and NK cells: two warriors confront each other</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>8</volume><issue>2</issue><spage>e1539617</spage><epage>e1539617</epage><pages>e1539617-e1539617</pages><issn>2162-4011</issn><issn>2162-402X</issn><eissn>2162-402X</eissn><abstract>Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerful warriors that can bring about the lysis of tumor cells through their cytotoxic ability. However, tumor cells have developed strategies to evade recognition mediated by NKs. Here, we review the mechanisms triggered by AML cells and discuss the emerging immunotherapeutic strategies that potentiate the anti-tumor functions of NKs.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>30713800</pmid><doi>10.1080/2162402X.2018.1539617</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2162-4011 |
| ispartof | Oncoimmunology, 2019-02, Vol.8 (2), p.e1539617-e1539617 |
| issn | 2162-4011 2162-402X 2162-402X |
| language | eng |
| recordid | cdi_pubmed_primary_30713800 |
| source | PubMed Central |
| subjects | Acute myeloid leukemia CAR-T immune checkpoints immunotherapy natural killer cells NKG2D Review |
| title | Acute myeloid leukemia and NK cells: two warriors confront each other |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T11%3A43%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20myeloid%20leukemia%20and%20NK%20cells:%20two%20warriors%20confront%20each%20other&rft.jtitle=Oncoimmunology&rft.au=Baraga%C3%B1o%20Raneros,%20Aroa&rft.date=2019-02-01&rft.volume=8&rft.issue=2&rft.spage=e1539617&rft.epage=e1539617&rft.pages=e1539617-e1539617&rft.issn=2162-4011&rft.eissn=2162-402X&rft_id=info:doi/10.1080/2162402X.2018.1539617&rft_dat=%3Cproquest_pubme%3E2179515324%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179515324&rft_id=info:pmid/30713800&rft_doaj_id=oai_doaj_org_article_ef89548a3bb047768200302b1b59fa08&rfr_iscdi=true |